Terms ending in 2044
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,178,876 | Conjugates Comprising Cleavable Linkers In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,337,038 | Conjugates Comprising Cleavable Beta-Glucuronide-Containing Linkers In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,758,555 | Pharmaceutical Formulations In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,686,707 | ANTI-STEAP2 Chimeric Antigen Receptors and Uses Thereof In force · High confidence | Medlmmune, LLC | In force | High confidence | |
| US 12,698,282 | Inhibitors of Myeloperoxidase In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,747,223 | N-(2-(3-Cyano-2-Azabicyclo[31.0]HEXAN-2-YL)-2-Oxoethyl)QUINOLINE-4-Carboxamides In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,653,828 | Polq Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.